Subscribe

Camurus AB (CAMX.ST)

SEK615.00 +88.50 (+16.81%)
SE STO Healthcare Medical - Pharmaceuticals
Address Ideon Science Park 223 70
Lund, AB, SE
CEO Sven Fredrik Tiberg
Website camurus.com
IPO 2015-12-03
ISIN SE0007692850

Explore sections of this company profile

Also trades on London Stock Exchange · 0RD1.L (SEK) Other OTC · CAMRF (USD) Stockholm Stock Exchange · CAMX.ST (SEK)
Description

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud’s phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM2056 that is in phase I clinical trials for the treatment of metabolic diseases; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity; and Gubra A/S to develop long-acting therapeutic option for the treatment of hypoparathyroidism; as well as NewBridge Pharmaceuticals. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
SEK615.00 +88.50 (+16.81%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
140.9K
Beta
0.51
Float Shares
36.60M
Free Float %
61.5%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+3.42% -8.21% -0.19% -7.14% -17.36% -16.01% -17.83% +93.38% +156.36% +753.86% +750.63%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
615.00
DCF (Unlevered) 319.52 -48.0%
DCF (Levered) 742.96 +20.8%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 1 0
Buy 6 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
36.51
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Medical - Pharmaceuticals: +7.8%
    +21.3% ★ Q1'26: -4.5% (vs Q1'25)
  • ✓
    EPS growth Medical - Pharmaceuticals: +20.2%
    +70.3% ★ Q1'26: -27.1% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%
    +27.5% ★ Q1'26: +23.0% (vs Q1'25)
  • ✓
    EBIT margin Medical - Pharmaceuticals: +6.8%
    +39.0% ★ Q1'26: +33.9% (vs Q1'25)
  • ✓
    ROIC Medical - Pharmaceuticals: +6.1%
    +113.3% ★ Q1'26: +86.2% (vs Q1'25)
  • ✗
    Share dilution Medical - Pharmaceuticals: +0.0%
    +0.9% Q1'26: -0.2% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×
    0.12× ★ Q1'26: 0.15× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.39) × ERP
WACC = 100% × Ke + 0% × Kd (5.4%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 319.52 Current price: 615.00
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
8 Rev. Ana.
4 EPS Ana. 		Dec 2027
8 Rev. Ana.
7 EPS Ana. 		Dec 2028
7 Rev. Ana.
6 EPS Ana. 		Dec 2029
3 Rev. Ana.
4 EPS Ana. 		Dec 2030
6 Rev. Ana.
2 EPS Ana.
Revenue
154.80M
est: 155.42M (-0.4%)
113.74M
est: 93.54M (+21.6%)
54.31M
est: 64.53M (-15.8%)
49.32M
est: 34.75M (+41.9%)
105.61M
est: 128.50M (-17.8%)
336.00M
est: 339.49M (-1.0%)
600.57M
est: 616.24M (-2.5%)
956.34M
est: 948.68M (+0.8%)
1.72B
est: 1.59B (+7.7%)
1.87B
est: 1.85B (+0.7%)
2.27B
est: 2.36B (-4.0%)
2.80B
2.65B – 3.03B
+18.7% YoY
4.08B
3.39B – 5.45B
+45.9% YoY
6.34B
6.22B – 6.46B
+55.2% YoY
8.53B
7.48B – 10.52B
+34.6% YoY
11.75B
10.30B – 14.48B
+37.7% YoY
EBITDA
-200.72M
est: -754.6K (-26,499.0%)
-98.83M
est: -454.1K (-21,663.5%)
-239.28M
est: -313.3K (-76,274.3%)
-284.70M
est: -168.7K (-168,647.1%)
-353.05M
est: -623.9K (-56,488.9%)
-196.58M
est: -1.65M (-11,826.7%)
-97.72M
est: -2.99M (-3,166.2%)
87.59M
est: -4.61M (+2,001.6%)
562.55M
est: 306.61M (+83.5%)
568.24M
est: 356.77M (+59.3%)
909.18M
est: 453.96M (+100.3%)
538.72M
509.98M – 583.39M
+18.7% YoY
786.02M
652.38M – 1.05B
+45.9% YoY
1.22B
1.20B – 1.24B
+55.2% YoY
1.64B
1.44B – 2.02B
+34.6% YoY
2.26B
1.98B – 2.79B
+37.7% YoY
EBIT
-204.27M
est: -3.07M (-6,547.7%)
-102.36M
est: -1.85M (-5,435.2%)
-243.37M
est: -1.28M (-18,976.2%)
-287.04M
est: -687.0K (-41,681.4%)
-359.98M
est: -2.54M (-14,069.8%)
-205.04M
est: -6.71M (-2,954.9%)
-110.40M
est: -12.18M (-806.2%)
74.34M
est: -18.76M (+496.3%)
550.58M
est: 287.35M (+91.6%)
553.61M
est: 334.35M (+65.6%)
884.17M
est: 425.43M (+107.8%)
504.88M
477.94M – 546.73M
+18.7% YoY
736.63M
611.39M – 982.44M
+45.9% YoY
1.14B
1.12B – 1.17B
+55.2% YoY
1.54B
1.35B – 1.90B
+34.6% YoY
2.12B
1.86B – 2.61B
+37.7% YoY
Net Income
-159.54M
est: -186.58M (+14.5%)
-80.99M
est: -123.39M (+34.4%)
-190.57M
est: -275.64M (+30.9%)
-234.68M
est: -317.32M (+26.0%)
-289.87M
est: -357.46M (+18.9%)
-167.27M
est: -178.16M (+6.1%)
-90.45M
est: -88.03M (-2.7%)
55.55M
est: 55.60M (-0.1%)
431.44M
est: 223.25M (+93.3%)
428.39M
est: 426.23M (+0.5%)
735.57M
est: 735.57M (+0.0%)
939.17M
725.23M – 997.42M
+27.7% YoY
1.75B
1.03B – 2.48B
+86.6% YoY
3.11B
2.18B – 3.85B
+77.3% YoY
3.64B
3.05B – 4.74B
+17.0% YoY
4.67B
3.92B – 6.08B
+28.4% YoY
SGA
31.35M
est: 64.77M (-51.6%)
42.72M
est: 38.98M (+9.6%)
72.48M
est: 26.89M (+169.5%)
122.88M
est: 14.48M (+748.5%)
194.01M
est: 53.55M (+262.3%)
269.40M
est: 141.48M (+90.4%)
239.81M
est: 256.82M (-6.6%)
308.79M
est: 395.37M (-21.9%)
424.45M
est: 508.16M (-16.5%)
583.72M
est: 591.28M (-1.3%)
708.15M
est: 752.35M (-5.9%)
892.84M
845.20M – 966.86M
+18.7% YoY
1.30B
1.08B – 1.74B
+45.9% YoY
2.02B
1.98B – 2.06B
+55.2% YoY
2.72B
2.39B – 3.35B
+34.6% YoY
3.75B
3.28B – 4.62B
+37.7% YoY
EPS
-5.51
est: -3.14 (-75.7%)
-1.99
est: -2.07 (+4.0%)
-4.68
est: -4.63 (-1.0%)
-5.77
est: -5.33 (-8.2%)
-6.23
est: -6.01 (-3.7%)
-3.18
est: -2.99 (-6.2%)
-1.66
est: -1.48 (-12.2%)
1.01
est: 0.99 (+2.0%)
7.78
est: 3.95 (+97.0%)
7.39
est: 6.63 (+11.5%)
12.42
est: 13.13 (-5.4%)
14.35
12.09 – 16.62
+9.3% YoY
26.46
17.15 – 41.27
+84.3% YoY
47.71
36.40 – 64.19
+80.4% YoY
60.60
50.90 – 78.94
+27.0% YoY
77.84
65.39 – 101.40
+28.4% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-13 B+ 3/5 4/5 4/5 5/5 3/5 1/5 1/5
2026-05-12 B+ 3/5 4/5 5/5 5/5 3/5 1/5 1/5
2026-05-11 B+ 3/5 4/5 5/5 5/5 3/5 1/5 1/5
2026-05-08 B+ 3/5 4/5 5/5 5/5 3/5 1/5 1/5
2026-05-07 B+ 3/5 4/5 5/5 5/5 3/5 1/5 1/5
2026-05-06 B+ 3/5 4/5 5/5 5/5 3/5 1/5 1/5
2026-05-05 B+ 3/5 4/5 5/5 5/5 3/5 1/5 1/5
2026-05-04 B+ 3/5 4/5 5/5 5/5 3/5 1/5 1/5
2026-04-30 B+ 3/5 4/5 5/5 5/5 3/5 1/5 1/5
2026-04-29 B+ 3/5 4/5 4/5 5/5 3/5 1/5 1/5
2026-04-28 B+ 3/5 4/5 4/5 5/5 3/5 1/5 1/5
2026-04-27 B 3/5 4/5 4/5 5/5 2/5 1/5 1/5
2026-04-24 B 3/5 4/5 4/5 5/5 2/5 1/5 1/5
2026-04-23 B 3/5 4/5 4/5 5/5 2/5 1/5 1/5
2026-04-22 B 3/5 4/5 4/5 5/5 2/5 1/5 1/5
2026-04-21 B 3/5 4/5 4/5 5/5 2/5 1/5 1/5
2026-04-20 B 3/5 4/5 4/5 5/5 2/5 1/5 1/5
2026-04-17 B 3/5 4/5 4/5 5/5 2/5 1/5 1/5
2026-04-16 B 3/5 4/5 4/5 5/5 2/5 1/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
824.10M
OE per share TTM
13.71
Owner's Yield
2.70%
Maintenance CapEx ratio
28.61%
Maint CapEx / Avg PPE
6.6%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 76 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 iShares OMX Stockholm Capped UCITS ETF OM3X.DE 0.26% 559.8K 0.10%
2 Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Dist X026.DE 0.17% 584.8K 0.23%
3 Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Acc CEM.PA 0.17% 584.8K 0.23%
4 iShares MSCI Europe Small-Cap ETF IEUS 0.14% 236.4K 0.41%
5 Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L 0.13% 4.53M 0.30%
6 Schwab International Small-Cap Equity ETF SCHC 0.09% 4.68M 0.06%
7 iShares Currency Hedged MSCI EAFE Small-Cap ETF HSCZ 0.06% 133.3K 0.83%
8 iShares MSCI EAFE Small-Cap ETF SCZ 0.06% 8.03M 0.40%
9 Vanguard FTSE All-World ex-US Small-Cap ETF VSS 0.05% 7.80M 0.06%
10 iShares $ Treasury Bond 3-7yr UCITS ETF CBUG.DE 0.04% 200.3K 0.10%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
3.19M
Shares Outstanding
59.51M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Fredrik Tiberg President, Chief Executive Officer, CSO & Director 13M male
Anders Fink Vadsholt Chief Financial Officer — male
Bo A. C. TarrasWahlberg Vice President of Legal & Group General Counsel — —
Fredrik Joabsson Chief Business Development Officer — male
Jane Buus Laursen Chief Corporate Development Officer — female
Maria Lundqvist Global Head of Human Resources — female
Markus Johnsson Senior Vice President of R&D — male
Rein Piir Vice President of Investor Relations — male
Richard Jameson Chief Commercial Officer — male
Alberto Pedroncelli Chief Medical Officer — male
Susanne Lagerlund Vice President of Technical Operations — female
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Pharmaceuticals